[Application of tacrolimus and cyclosporine A in HBV-carrying renal transplant recipients].
OBJECTIVE
To compare the long-term effect and safety of tacrolimus (FK506) and cyclosporine (CsA) in kidney transplant (KT) recipients carrying hepatitis B Virus(HBV).


METHODS
A total of 109 patients with HBV were randomized into FK506 group (52 cases) and CsA group (57 cases) after KT, and a 2-year-long follow-up of the patients was conducted to record the patient and graft survival, incidence of acute graft rejection and postoperative liver function.


RESULTS
The 2-year patient/graft survival was 86.0%/73.7% and 94.2%/90.3% in CsA and FK506 groups, respectively (P<0.05), with incidence of acute rejection of 10.5% and 9.6% (P>0.05), and rate of abnormal liver function of 26.3% and 15.4% (P<0.05), respectively. Eight patients (14.4%) in CsA group required a drug conversion but none in FK506 group. The drug conversion resulted in significant reduction of ALT/AST level from 255.13+/-31.38/201.88+/-21.25 U/L to 31.25+/-11.50/25.13+/-9.68 U/L (P<0.01).


CONCLUSIONS
For HBV-carrying renal transplant recipients, FK506 as the primary choice of immunosuppressant can be more effective and safer than CsA.
Department of Kidney Transplantation, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Xiao-you
XY
Liu
Li-xin
LX
Yu
Shao-jie
SJ
Fu
Jian
J
Xu
Chuan-fu
CF
Du
Wen-feng
WF
Deng
Yi-bin
YB
Wang
Gui-rong
GR
Ye
Yan-xuan
YX
Zhang
D000293:Adolescent; D000328:Adult; D002353:Carrier State / Q000503:physiopathology; D016572:Cyclosporine / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006084:Graft Rejection; D006514:Hepatitis B Surface Antigens / Q000378:metabolism; D006515:Hepatitis B virus; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects; D008099:Liver / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D055815:Young Adult
D006514:Hepatitis B Surface Antigens; D016572:Cyclosporine; D016559:Tacrolimus